AU780538B2 - Inhibitors of endo-exonuclease activity for treating cancer - Google Patents

Inhibitors of endo-exonuclease activity for treating cancer Download PDF

Info

Publication number
AU780538B2
AU780538B2 AU13765/01A AU1376501A AU780538B2 AU 780538 B2 AU780538 B2 AU 780538B2 AU 13765/01 A AU13765/01 A AU 13765/01A AU 1376501 A AU1376501 A AU 1376501A AU 780538 B2 AU780538 B2 AU 780538B2
Authority
AU
Australia
Prior art keywords
endo
agent
exonuclease
patient
pentamidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU13765/01A
Other languages
English (en)
Other versions
AU1376501A (en
Inventor
Terry Chow
David Griller
Chiaoli Yeh
Leonard Yuen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncozyme Pharma Inc
Original Assignee
Oncozyme Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncozyme Pharma Inc filed Critical Oncozyme Pharma Inc
Publication of AU1376501A publication Critical patent/AU1376501A/en
Application granted granted Critical
Publication of AU780538B2 publication Critical patent/AU780538B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU13765/01A 1999-11-16 2000-11-16 Inhibitors of endo-exonuclease activity for treating cancer Ceased AU780538B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16568899P 1999-11-16 1999-11-16
US60/165688 1999-11-16
PCT/CA2000/001355 WO2001035935A2 (en) 1999-11-16 2000-11-16 Inhibitors of endo-exonuclease activity such as pentamidine for the treatment of cancer

Publications (2)

Publication Number Publication Date
AU1376501A AU1376501A (en) 2001-05-30
AU780538B2 true AU780538B2 (en) 2005-03-24

Family

ID=22600019

Family Applications (1)

Application Number Title Priority Date Filing Date
AU13765/01A Ceased AU780538B2 (en) 1999-11-16 2000-11-16 Inhibitors of endo-exonuclease activity for treating cancer

Country Status (12)

Country Link
US (2) US20060276548A1 (enExample)
EP (1) EP1231910B1 (enExample)
JP (1) JP2003515534A (enExample)
AT (1) ATE431734T1 (enExample)
AU (1) AU780538B2 (enExample)
CA (1) CA2388674C (enExample)
CY (1) CY1110503T1 (enExample)
DE (1) DE60042245D1 (enExample)
DK (1) DK1231910T3 (enExample)
ES (1) ES2327313T3 (enExample)
PT (1) PT1231910E (enExample)
WO (1) WO2001035935A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1355637A2 (en) * 2000-06-21 2003-10-29 Georgetown University Medical Center Inhibitors of matriptase for the treatment of cancer
US6569853B1 (en) 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
US6693125B2 (en) 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
US8053477B2 (en) * 2002-03-29 2011-11-08 University Of Maryland, Baltimore Inhibitors of the S100-p53 protein-protein interaction and method of inhibiting cancer employing the same
ITMI20021455A1 (it) * 2002-07-02 2004-01-02 Ugo Raffaello Citernesi Formulazioni fosfolipidiche di lexitropsine loro preparazione ed impiego terapeutico
US20050054708A1 (en) * 2003-07-28 2005-03-10 Nichols Matthew James Combinations of drugs for the treatment of neoplasms
AU2005228410A1 (en) 2004-03-29 2005-10-13 University Of South Florida Effective treatment of tumors and cancer with triciribine and related compounds
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
US20110008327A1 (en) 2004-03-29 2011-01-13 Cheng Jin Q Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
US20100009928A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and taxanes and methods of use thereof
US20100173864A1 (en) 2004-03-29 2010-07-08 Cheng Jin Q Compositions including triciribine and one or more platinum compounds and methods of use thereof
US20100028339A1 (en) 2004-03-29 2010-02-04 Cheng Jin Q Compositions including triciribine and trastuzumab and methods of use thereof
KR20070092972A (ko) * 2004-12-10 2007-09-14 테무릭크 가부시키가이샤 전이암 치료제 및 암 전이 억제제
WO2009086485A1 (en) 2007-12-28 2009-07-09 Server Technology, Inc. Power distribution, management, and monitoring systems and methods
RU2011142806A (ru) * 2009-05-01 2013-06-10 ОНКОЗИМ ФАРМА ИНК. (Канада) Комбинации пентамидина для лечения рака
WO2014008592A1 (en) * 2012-07-13 2014-01-16 Oncozyme Pharma Inc. Combinations comprising diamidine compounds and parp inhibitors for use iν treating cancer
WO2019095046A1 (en) 2017-11-16 2019-05-23 Montdorex Inc. Mono- and di-amidine endo-exonuclease inhibitors and methods for inhibiting endo-exonuclease activity
CN111671904B (zh) * 2020-04-15 2022-12-06 四川大学华西第二医院 一种含有抑制核酸内切酶功能的药物及其抗肿瘤的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5084480A (en) * 1987-11-06 1992-01-28 Fujisawa Usa, Inc. Pentamidine salts useful in the treatment of pneumocystis carinii pneumonia
US5204113A (en) * 1987-04-09 1993-04-20 Fisons Plc Pharmaceutical compositions containing pentamidine
US5489524A (en) * 1991-03-26 1996-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric protein that has a human Rho motif and deoxyribonuclease activity

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2145528C3 (de) * 1971-09-11 1981-12-17 Heinrich Mack Nachf., 7918 Illertissen Exonuclease und diese enthaltendes cytostatisches Mittel
EP0585957A1 (en) * 1986-08-06 1994-03-09 Ajinomoto Co., Inc. Recombinant B-cell differentiation factor
ATE77947T1 (de) * 1987-04-09 1992-07-15 Fisons Plc Pentamidin enthaltende pharmazeutische zusammensetzungen.
US5585363A (en) * 1987-05-05 1996-12-17 City Of Hope Circumvention of human tumor drug resistance
US5166140A (en) * 1987-05-05 1992-11-24 City Of Hope Use of certain nucleoside analogs to attenuate cancer cell resistance to DNA damaging chemotherapy
US4856528A (en) * 1987-06-26 1989-08-15 John Hopkins University Tumor volume determination
US5204352A (en) * 1987-09-29 1993-04-20 The United States Of America As Represented By The Secretary Of The Army Compounds exhibiting anti-parasitic activity and a method for their use
US5422120A (en) * 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
MX16687A (es) * 1988-07-07 1994-01-31 Ciba Geigy Ag Compuestos de biarilo y procedimiento para su preparacion.
US5037758A (en) * 1989-01-11 1991-08-06 Her Majesty The Queen In Right Of Canada, As Represented By The National Research Council Of Canada Enhanced production of biosurfactant through the use of a mutated B subtilis strain
GB8903438D0 (en) * 1989-02-15 1989-04-05 May & Baker Ltd New compositions of matter
US5352581A (en) * 1989-03-24 1994-10-04 United States/National Institutes Of Health Sensitive yeast genetic system for identifying agents causing double-stranded DNA damage
AU7162791A (en) * 1989-12-27 1991-07-24 Miroslav Radman Novel system for isolating and producing new genes, gene products and dna sequences
US5324830A (en) * 1991-03-26 1994-06-28 United States Of America Chimeric protein that has a human RHo Motif and deoxyribonuclease activity
US5283238A (en) * 1992-04-24 1994-02-01 Immtech International, Inc. Methods of treating cancer using modified C-reactive protein
US5723288A (en) * 1994-05-06 1998-03-03 The University Of North Carolina At Chapel Hill Method of fluorescent detection of nucleic acids and cytoskeleton elements using bis-dicationic aryl furans, and kits useful therefor
US5874283A (en) * 1995-05-30 1999-02-23 John Joseph Harrington Mammalian flap-specific endonuclease
US5698556A (en) * 1995-06-07 1997-12-16 Chan; Carcy L. Methotrexate analogs and methods of using same
US5643935A (en) * 1995-06-07 1997-07-01 The University Of North Carolina At Chapel Hill Method of combatting infectious diseases using dicationic bis-benzimidazoles
US5916779A (en) * 1995-09-21 1999-06-29 Becton, Dickinson And Company Strand displacement amplification of RNA targets
US5935982A (en) * 1997-02-28 1999-08-10 The University Of North Carolina At Chapel Hill Methods of treating retroviral infection and compounds useful therefor
US5977311A (en) * 1997-09-23 1999-11-02 Curagen Corporation 53BP2 complexes
KR100631766B1 (ko) * 1997-10-07 2006-10-09 오노 야꾸힝 고교 가부시키가이샤 폴리펩티드, 그 폴리펩티드를 암호화하는 ｃＤＮＡ 및그들의 용도
US7115665B1 (en) * 2000-11-16 2006-10-03 Onocozyme Pharma, Inc. Inhibitors of endo-exonuclease activity for treating cancer
EP1263942B1 (en) * 2000-03-08 2013-11-06 Novozymes A/S Variants with altered properties
US6569853B1 (en) * 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
US6693125B2 (en) * 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
US20040010045A1 (en) * 2001-09-07 2004-01-15 Taolin Yi Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer
US8053477B2 (en) * 2002-03-29 2011-11-08 University Of Maryland, Baltimore Inhibitors of the S100-p53 protein-protein interaction and method of inhibiting cancer employing the same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204113A (en) * 1987-04-09 1993-04-20 Fisons Plc Pharmaceutical compositions containing pentamidine
US5084480A (en) * 1987-11-06 1992-01-28 Fujisawa Usa, Inc. Pentamidine salts useful in the treatment of pneumocystis carinii pneumonia
US5489524A (en) * 1991-03-26 1996-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric protein that has a human Rho motif and deoxyribonuclease activity

Also Published As

Publication number Publication date
ES2327313T3 (es) 2009-10-28
US20090068094A1 (en) 2009-03-12
DE60042245D1 (de) 2009-07-02
DK1231910T3 (da) 2009-08-31
EP1231910B1 (en) 2009-05-20
ATE431734T1 (de) 2009-06-15
JP2003515534A (ja) 2003-05-07
WO2001035935A2 (en) 2001-05-25
EP1231910A2 (en) 2002-08-21
PT1231910E (pt) 2009-08-06
WO2001035935B1 (en) 2002-02-07
CA2388674A1 (en) 2001-05-25
CA2388674C (en) 2005-01-25
WO2001035935A3 (en) 2002-01-03
AU1376501A (en) 2001-05-30
CY1110503T1 (el) 2015-04-29
US20060276548A1 (en) 2006-12-07

Similar Documents

Publication Publication Date Title
US20090068094A1 (en) Inhibitors of endo-exonuclease activity for treating cancer
Mabuchi et al. Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model
US6689787B1 (en) Method of using an integrin antagonist and radiation therapy as combination therapy in the treatment of neoplasia
Kim et al. Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice
WO2019126739A1 (en) Pyrvinium pamoate anti-cancer therapies
WO1995000129A1 (en) Treatment of multidrug resistant diseases
US20100056625A1 (en) Non-toxic anti-cancer drug combining ascorbate, magnesium and a naphthoquinone
Zhou et al. Mitochondria Energy Metabolism Depression as Novel Adjuvant to Sensitize Radiotherapy and Inhibit Radiation Induced‐Pulmonary Fibrosis
KR20100043242A (ko) 인테그린 리간드를 사용하는 암치료용 특이적 요법 및 의약
WO2019109074A1 (en) Mebendazole cancer therapies and methods of use
KR20180121571A (ko) Liv1-adc와 화학요법제를 사용한 병용 요법
JP2023065427A (ja) 白金耐性癌の治療
Muñoz et al. Triple negative breast cancer: how neurokinin-1 receptor antagonists could be used as a new therapeutic approach
WO1997027848A9 (en) SENSITIZATION OF HER2/neu OVER-EXPRESSING CANCER CELLS TO CHEMOTHERAPEUTIC DRUGS
EP0877608A1 (en) SENSITIZATION OF HER2/neu OVER-EXPRESSING CANCER CELLS TO CHEMOTHERAPEUTIC DRUGS
TW200908976A (en) Cancer treatment combination therapy comprising vinflunine and trastuzumab
US7115665B1 (en) Inhibitors of endo-exonuclease activity for treating cancer
CN113329772B (zh) 化学疗法与重组齐整小核菌凝集素的联合疗法
WO2020234454A1 (en) Combination treatment of cancer targeting energy metabolism and intracellular ph
Huang et al. Synergistic effect of hyperthermia and neferine on reverse multidrug resistance in adriamycin-resistant SGC7901/ADM gastric cancer cells
CN111542325A (zh) 用于治疗恶性肿瘤和癌前病症的组合物及其使用方法和制备药剂的方法
CA2483352A1 (en) Inhibitors of endo-exonuclease activity for treating cancer
JP5393691B2 (ja) 急性ヒト骨髄性白血病細胞を死滅させるトロンボポエチン受容体作用薬（ＴｐｏＲＡ）
CN104815322A (zh) 用于头颈部肿瘤联合治疗的制剂及其用途
JPWO2006035515A1 (ja) 膀胱表在性癌の治療又は予防用医薬組成物、及びその利用